Clinical Research

临床研究计划（CRP）在Lineberger综合癌症中心吸引了来自不同的癌症相关临床学科有成就的学术教师，以促进临床和实验室相关的研究。CRP的发展治疗组（DTG）是CRP的中心，因为RT将临床试验教师与主要疾病特定条目的代表聚集在一起，以设计和实施研究启动的临床试验和相关科学。在过去的6年中，在GI，GU，血液学，黑色素瘤和胸部恶性肿瘤以及乳腺癌方面建立了特别的优势，现在是第二个临床研究和转化计划。CRP还整合了基础科学和人口科学中出现的转化概念，将其嵌入人类研究中。我们面向临床试验的国家认可的生物统计学家小组， 分析LCCC CRP研究，同时在临床试验方法学方面拥有出色的同行评审资金。 CRP开发和管理研究者发起的、NCI合作组和制药公司申办的试验，尽可能整合药理学、分子学、遗传学、行为学和流行病学终点。其71名成员来自11个部门和学校。我们通过以下方式整合科学 疾病部位，同时包括跨外科，放射，内科，儿科和妇科肿瘤学的研究问题，以及方法和成像问题。我们的项目为NCI提供高级领导，Tepper，Goldberg，Socinski和Carey博士被任命为CTAC指导委员会成员。 2009年的方案总费用供资为2 300万美元，其中包括国家癌症研究所供资610万美元。2004- 2009年，出版物总数为1，532份;其中21%为方案内出版物，24%为方案间出版物。在过去六年中，治疗性临床试验从380项增加到848项。CRP重点包括乳腺癌和GI SPORE，肝细胞癌和肾癌的新兴努力， 基因组阵列在多种癌症中的能力，多中心的国防部资助的前列腺癌，P-01侧重于临床试验方法，招聘全国公认的乳腺癌和老年肿瘤学研究人员，Hy Muss，并在个性化治疗的研究，由新招募的霍华德麦克劳德领导。CRP通过充当人体临床试验的管道和临床和实验的联系， 为整个LCCC会员服务的科学研究。

The Clinical Research Program (CRP) at the UNC Lineberger Comprehensive Cancer Center attracts accomplished academic faculty from diverse cancer related clinical disciplines to foster clinical and laboratory linked research. The CRP's Developmental Therapeutics Group (DTG) is CRP's hub, as rt brings together clinical trials faculty with representation from the major disease specific entries to design and implement investigation-initiated clinical trials and correlative science. Over the past 6 years particular strength has been built in Gl, GU, hematologic, melanoma, and thoracic malignancies, as well as Breast Cancer, which is now a second clinical research and translational program. The CRP also integrates translational concepts that emerge from the basic and population sciences, embedding them in human studies research. Our clinical trials oriented group of nationally recognized biostatisticians both design and analyze LCCC CRP studies while having outstanding peer-reviewed funding In clinical trials methodology. The CRP develops and manages investigator initiated, NCI cooperative group, and pharmaceutical company sponsored trials, whenever possible integrating pharmacologic, molecular, genetic, behavioral, and epidemiologic endpoints. Its 71 members come from 11 departments and schools. We integrate science by disease site while including research issues across the spectrum of surgical, radiation, medical, pediatric, and gynecologic oncology, as well as methodology and imaging questions. Our program is providing senior leadership to NCI wrth Drs. Tepper, Goldberg, Socinski and Carey appointed to CTAC steering committees. Program total cost funding in 2009 was $23.0 million, including $6.1 million in NCI funding. In 2004-9, the total number of publications were 1,532; 21% of which were intraprogrammatic and 24% were interprogrammatic. Therapeutic Clinical trials accrual rose from 380 to 848 during the last six years. CRP highlights include Breast and Gl SPOREs, emerging efforts in hepatocellular and renal cancers, outstanding genomic array capabilities in multiple cancers, a multi-center DOD grant in prostate cancer, a P-01 focusing on clinical trials methodology, recruitment of a nationally recognized Breast Cancer and Geriatric Oncology researcher, Hy Muss, and studies in individualized therapy, led by new recruit Howard McLeod. The CRP adds value to the UNC LCCC by acting as the human clinical trials conduit and nexus for clinical and scientific studies that serve the whole LCCC membership.